Addendum
Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Addendum to Project A24-46
Report documents
-
Addendum
Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Addendum to Project A24-46
Dossier assessment
Adults with resectable non-small cell lung cancer with tumour cell PD-L1 expression < 1% at high risk of recurrence; pembrolizumab in combination with platinum-based chemotherapy (neoadjuvant) and subsequent monotherapy (adjuvant)
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
17.10.2024 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A24-93
- Commission
- Commission awarded on 10.09.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A24-93_en
Connected Projects
-
Dossier assessment
Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Addendum
Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Second Addendum to Project A24-46
Status: Commission completed